Genscript Biotech valuation

1548 · HKEX · HKD

Compare Genscript Biotech
$27.76Change from previous close: −7.96%Absolute change: −$2.40

Close · November 20, 2026

Valuation

The average price target of 6 analysts is $45.43.

Data as of November 21, 2026

Genscript Biotech compared with similar companies

Genscript Biotech's Forward P/E: 76.9, +142% against the median of a group of 10 similar companies (31.7).

Genscript Biotech's metrics compared with similar companies
MetricGenscript BiotechMedian25th–75th percentileBand
Forward P/E76.931.720.4 – 43.6High
EV/EBITDA340.037.918.2 – 67.6High
Price/book2.165.242.69 – 8.16Low
Price/sales81.48.894.67 – 31.6High
Gross margin52.0%74.6%49.8% – 79.1%Middle
Operating margin14.9%14.9%6.8% – 30.3%Middle
Net margin-75.4%7.8%5.4% – 21.4%Low
ROE-15.3%10.4%5.0% – 19.8%Low
Debt/equity0.090.110.05 – 0.40Middle

Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.

TickerLandia analysisHow it is calculated

Companies in the group: same industry, similar size

Other metrics

Valuation multiples

Market cap
$68.78B
Enterprise value
$65.49B
P/E (trailing 12 months)
-13.0
EV/revenue
77.5

Profitability and growth

ROA
1.5%
ROIC
1.7%
Revenue growth (year over year)
-22.1%
Earnings growth (year over year)
174.4%

Financial health

Total cash
$810.27M
Total debt
$343.53M
Current ratio
1.53
Quick ratio
1.33
Altman Z-Score
3.58
Piotroski F-Score
4.00

Dividends

Payout ratio
0.0%
Ex-dividend date
June 5, 2017

Analysts and estimates

Average price target
$45.43
Median price target
$38.53
High price target
$87.95
Low price target
$29.99
Analysts with a price target
6
Forward EPS
$0.39
EPS estimate, current year
$0.03

Shares and trading

Beta
0.92
Average volume
42.3M
Shares outstanding
2.28B
Float
1.41B
Institutional ownership
29.0%
Insider ownership
35.2%